Manufacturing of cell therapies is a time consuming and expensive proposition. Optimizing manufacturing processes involves establishing culture parameters to reduce time and expense while providing a phenotype that delivers the intended efficacy. One of the more critical elements of cell manufacturing remains the growth supplements required for optimal growth. Traditionally, fetal bovine serum (FBS) has been the work-horse of cell culture. Alternatively, human derived supplements from processed blood have been growing in usage across the field.